Oral FT-4202 Safe, Found to Improve Red Blood Cell Function in SCD
News
FT-4202, a potential disease-modifying oral treatment for sickle cell disease (SCD), is well-tolerated in people with SCD and induces improvements in several red blood cell parameters, early clinical trial data ... Read more